Previous Article | Next Article ![]()
Molecular and Cellular Biology, April 2006, p. 2746-2757, Vol. 26, No. 7
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.7.2746-2757.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
GSF-National Research Center for Environment and Health, Institute of Human Genetics, Neuherberg/Munich, Germany,1 Institute of Animal Physiology, Ludwig-Maximilians University, Munich, Germany2
Received 13 September 2005/ Returned for modification 17 October 2005/ Accepted 11 January 2006
| ABSTRACT |
|---|
|
|
|---|
-1 and RET are expressed on retinal Mueller glial cells (RMG) but not on photoreceptors. Additionally, RMG express the receptors for the GDNF family members artemin and neurturin (GFR
-2 and GFR
-3). We further investigated GDNF-, artemin-, and neurturin-induced signaling in isolated primary RMG and demonstrate three intracellular cascades, which are activated in vitro: MEK/ERK, stress-activated protein kinase (SAPK), and PKB/AKT pathways with different kinetics in dependence on stimulating GFL. We correlate the findings to intact porcine retina, where GDNF induces phosphorylation of ERK in the perinuclear region of RMG located in the inner nuclear layer. GDNF signaling resulted in transcriptional upregulation of FGF-2, which in turn was found to support photoreceptor survival in an in vitro assay. We provide here a detailed model of GDNF-induced signaling in mammalian retina and propose that the GDNF-induced rescue effect on mutated photoreceptors is an indirect effect mediated by retinal Mueller glial cells. | INTRODUCTION |
|---|
|
|
|---|
1-4 coreceptors that are either linked to the plasma membrane by a glycosyl phosphatidylinositol (GPI) anchor or, by cleavage through an unknown protease, provided as a soluble coreceptor. All four different GFLs (GDNF, NRTN, ARTN, and PSPN) signal via the activation of the RET receptor tyrosine kinase, a single-pass transmembrane protein containing four cadherin-like repeats in the extracellular domain and a typical intracellular tyrosine kinase domain (reviewed in reference 2). GDNF is widely distributed in the central and peripheral nervous systems and is also expressed in the inner ear, olfactory epithelium, carotid body, kidney, and gastrointestinal tract (38). In the eye, GDNF is primarily expressed in the retina, and several investigators have shown its potential therapeutic value by providing neuroprotection in the context of retinal degeneration. GDNF has been shown to rescue retinal ganglion cells after axotomy (29, 55) and has been proven very effective in retarding retinal PR degeneration in the rd1 mouse (19). Subretinal application of GDNF has led to decreased loss of PR, as well as a significant functional rescue, shown by recordable ERG on PN22 compared to untreated animals. Recent evidence has proposed that neurotrophic rescue of PR may be indirect, mediated by interaction of neurotrophic factors with retinal Mueller glial cells (RMG), which in turn release or present secondary factors acting directly on PR (20, 21, 53; reviewed in reference 7). Upon subretinal injection of GDNF in the rd1 mouse, RMG react by upregulation of glial fibrillary acidic protein (19), indicating that GDNF-induced regulation in RMG gene expression and subsequent effects on PR may be mediated through an indirect pathway.
To elucidate the role of RMG in GDNF-mediated protection of PR, we analyzed expression and activity of transducer elements involved in GDNF signaling in porcine retina and further analyzed candidate target genes of GDNF signaling.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Immunolabeling. Porcine eyes were fixed in 10% formalin. For adequate and fast fixation, both cornea and lens were removed and the aqueous humor was replaced by fixative. After dehydration, the eyes were embedded in paraffin.
Tissue sections (5 µm) were mounted on coated slides (Super Frost Plus), deparaffinized, and rehydrated. High-temperature antigen retrieval was performed using 1 mM EDTA buffer, pH 8.0, as described previously (37). Slides were rinsed in phosphate-buffered saline (PBS) with 0.1% Tween 20 (PBS-T; pH 7.3), and nonspecific binding was blocked with 3% bovine serum albumin (BSA) in PBS-T. Sections were then incubated with primary antibodies from R&D (anti-RET, anti-GFR
-1, anti-GFR
-2, and anti-GFR
-3 at 1:200 in 3% BSA-PBS-T) overnight at 4°C in a humid chamber, followed by incubation with Alexa 546 donkey anti-goat immunoglobulin G (IgG) conjugate (1:200; Molecular Probes) and DAPI (4',6'-diamidino-2-phenylindole; 200 nM; Sigma) for 2 h at room temperature. After washing, sections were incubated for another 8 h at 4°C with primary antibodies anti-glutamine-synthetase (anti-GS) (1:500; Transduction Laboratories) or anti-GLAST (1:200; Alpha Diagnostic), followed by incubation for 2 h with Alexa 488 anti-mouse or anti-rabbit IgG, respectively, and, after final washing, mounted in FluorSave (Calbiochem). Images were obtained with a Zeiss APO-TOME.
Immunolabeling on GDNF-stimulated retina sections. Retinae were dissected from porcine eyes as described previously (18), cut into equal pieces, and placed into 12-well dishes containing Dulbecco's modified Eagle's medium combined with F-12 medium (DMEM/F-12; GIBCO) at one piece per well. After an initial incubation phase (10 min), stimulation was performed with 100 ng/ml GDNF (PeproTech) in DMEM/F-12 or medium alone. After the indicated time points, the medium was replaced by ice-cold paraformaldehyde (4% in PBS, 5% sucrose) and the tissue was fixed for 1 h at 4°C. Cryopreservation was performed by incubation for 1 h each in 5% and 10% sucrose in PBS, followed by incubation overnight in 20% sucrose in PBS, all at 4°C. The tissue samples were frozen in TissueTek on liquid nitrogen and stored at 80°C. Tissue pieces were sectioned at 10 µm in a cryostat, collected on gelatin-coated Super Frost slides, and stored at 20°C.
For immunolabeling, sections were rinsed in PBS and incubated for 10 min in 0.1% Triton 100 in PBS, followed by blocking for 30 min in 3% BSA in PBS-T. Incubation with primary antibodies (anti-pERK, 1:250 [Cell Signaling Technology]; or anti-GS at 1:500 [BD Transduction Laboratories], diluted in 3% BSA-PBS-T) was done overnight at 4°C and then followed by incubation with Alexa 488/568-coupled secondary antibodies (1:200; Molecular Probes) for 2 h at room temperature. After a final washing, sections were mounted in FluorSave (Calbiochem) and images were obtained with a Zeiss Axioskop II. pERK-positive cells within the inner nuclear layer (INL) were counted on two visual fields (x100 magnification) per section, there were 10 different sections per experiment, and the experiments were repeated twice.
NCAM immunolabeling. Paraformaldehyde-fixed retinae were cryopreserved, sectioned at 10 µm, and stored at 80°C. Immunolabeling was performed as described above, with anti-neural cell adhesion molecule (NCAM) antibody (MAB2120Z, 1:200; Chemicon), followed by anti-mouse Alexa 488-coupled secondary antibody.
Statistical significance. Statistical significance was calculated using the Peritz F parametric test (22).
Isolation and in vitro culturing of primary RMG. RMG were isolated from porcine eyes employing a panning method as described previously (23) and cultured in DMEM/HEPES (GIBCO) with 10% fetal calf serum (FCS) to confluence (2 to 3 weeks). The purity of these cultures is above 97% (22).
Stimulation of RMG and preparation of cell lysates. One day prior to stimulation, RMG were washed, transferred into serum-free medium (DMEM/HEPES; GIBCO), and stimulated with either GDNF (100 ng/ml; PeproTech), NRTN (100 ng/ml; PeproTech), or ARTN (100 ng/ml; PeproTech) for the indicated time points. Inhibitors were applied 20 min both prior to and during stimulation at the following concentrations: U0126 (Promega), 10 µM; and LY294002 (Promega), 50 µM. For phosphotyrosine detection, stimulation was performed in the presence of phosphatase inhibitor cocktail 2 (Sigma), composed of sodium orthovanadate, sodium molybdate, sodium tartrate, and imidazole. Stimulation was stopped by addition of liquid nitrogen, and lysates were then prepared by addition (per 10-cm dish) of 300 µl lysis buffer (50 mM Tris, pH 7.4, 250 mM NaCl, 25 mM EDTA, 1% NP-40, 10% glycerol, and Complete protease inhibitor cocktail; Roche), including phosphatase inhibitor cocktail 2 (Sigma). Protein content of the lysates was determined by Bradford assay.
Photoreceptor preparation and survival assay. Porcine PR were prepared as described elsewhere (18), with the following slight modifications: enzymatic digestion of retinal pieces was stopped by addition of DMEM/F-12 medium (GIBCO) supplemented with 2% FCS. PR were collected from supernatant and plated at 1.3 x 105 cells per well onto precoated Falcon 96-well plates that were first coated with p-lysine (2 µg/cm2, 3 h; Sigma) followed by laminin (1 µg/cm2, overnight; BD Bioscience). Different concentrations of FGF-2 (20 ng/ml, 100 ng/ml, 500 ng/ml, or 1,000 ng/ml; purified FGF-2 from bovine brain; R&D) or respective GFLs (GDNF, NRTN, or ARTN, all 100 ng/ml and 500 ng/ml; PeproTech) in DMEM/F-12 medium or medium alone were applied on attached PR 20 h after preparation. PR survival was monitored by performing an esterase calcein-fluorophore assay (Molecular Probes), whereby living cells fluoresce bright green. Fluorescence was measured daily on a different row of the plate using a fluorescence reader (BioTek; Synergy HT). All values were compared to initial fluorescence at the beginning of the survival assays. Relative fluorescence was calculated as a percentage of initial fluorescence, whereby every value is a mean of two to four wells per day. Every experiment was performed at least in triplicate.
Western blots. Protein lysates (10 µg) of RMG were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted semidry onto polyvinylidene difluoride membranes. Unspecific binding was blocked for 1 h with 5% BSA in TBS-T. Blots were incubated with primary antibodies in 5% BSA-TBS-T overnight at 4°C [anti-pTyr100, 1:1,000; anti-pMEK1/2, 1:1,000; anti-pERK, 1:5,000; anti-pSAPK (stress-activated protein kinase), 1:2,000; or anti-pAKT (Ser473), 1:1,000] (Cell Signaling Technology), washed, and incubated in horseradish peroxidase-coupled secondary antibodies (1:15,000; Jackson Laboratories). Signal was developed with the ECL+ enhanced chemiluminescence kit (Amersham) according to the manufacturer's instructions and detected on Hyperfilm ECL (Amersham). Blots were stripped and reprobed with actin (1:1,000; Oncogene) or vimentin (clone V9, 1:1,000; Sigma) antibodies to verify equivalent protein loading.
RT-PCR.
Total RNA was prepared from retina, RMG (either directly after the panning procedure or from confluent cultures), or PR with an RNeasy kit (QIAGEN) according to the manufacturer's instructions. Reverse transcription (RT) was performed with the RT kit (QIAGEN), and 70 ng cDNA was set for PCR (annealing at 65°C, 35 cycles) with the following primers: RET for (CTGGACTCCATGGAGAACC) and RET rev (TCCAGGTCTTTGCTGATGTC), product size, 929 bp; GFR
-1 for (TAAAGGAAAACTACGCTGACTGCC) and GFR
-1 rev (TGCCCGACACATTGGATTTC), product size, 353 bp; GFR
-2 for (TTTGTCGTGAGCTCTGTGAAGC) and GFR
-2 rev (GCATGATTGGGTCCGAGATAAC), product size, 388 bp; GFR
-3 for (AGGAGCCTTCAGTCCCCAAG) and GFR
-3 rev (TGAGGCAGCGATCCCAATC), product size, 200 bp; GDNF for (CAGTGACTCAAATATGCCAGAGGA) and GDNF rev (AGATACATCCACACCTTTTAGCGG), product size, 491 bp; vimentin for (GTTTCCAAGCCTGACCTCAC) and vimentin rev (AATCTCATCCTGCAGGCG), product size, 335 bp; rhodopsin for (GGCTTCCCCATCAACTTCCTC) and rhodopsin rev (GTGGCTGACTCCTGCTGCTG), product size, 534 bp; GS for (GACTGCGCTGCAAGACCCG) and GS rev (ATGTGGTACTGGTGCCGCTTG), product size, 699 bp; GLAST for (ATTGTTGAGATGGAAGACATGGGAGTGATTG) and GLAST rev (TGGCTGTGATGCTGATGGTGATAATCTGTC), product size, 400 bp; and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) for (CGGGAAGCTTGTCATCAATGG) and GAPDH rev (GGCAGTGATGGCATGGACTG), product size, 358 bp. Products were of the expected sizes and were sequenced for identity verification.
Northern blot analysis. One day prior to stimulation, RMG were washed, transferred into serum-free medium (DMEM/HEPES), and stimulated for 24 h with GDNF (100 ng/ml; PeproTech). Northern blotting was performed as described elsewhere (42). Briefly, total RNA was prepared with the RNeasy kit (QIAGEN), and examination of integrity and quantification were performed with an RNA-nano chip on a 2100 Bioanalyzer (Agilent). Equal amounts (5 µg) were loaded onto formaldehyde gels, resolved, and blotted. Detection of FGF-2 transcript was performed by generation of an FGF-2-specific digoxigenin (DIG)-labeled RNA with a DIG labeling kit (Roche) using an RT-PCR product generated from RMG with the following primers: FGF-2 for (CAAGCGGCTGTACTGCAAAAAC) and FGF-2 T7 promoter rev (TAATACGACTCACTATAGGATGTGGCCATTAAAATCAGCTCTT). The detected transcript was approximately 6 kbp and thus similar in size to that of the full-length human transcript (6.774 kbp, ENST00000264498; http://www.ensembl.org/).
FGF-2 ELISA. RMG were seeded onto 96-well culture plates at 2 x 104 cells per well, incubated for 24 h in DMEM/25 mM HEPES in the presence of 10% FCS, and then, prior to stimulation, incubated for an additional 24 h without FCS. RMG were then left either unstimulated or stimulated with GDNF, NRTN, or ARTN (all 100 ng/ml; PeproTech) in the absence or presence of U0126 (10 µM; Promega) for 16 h. Medium from the wells was collected after stimulation, and the amount of secreted FGF-2 was analyzed by an FGF-2 enzyme-linked immunosorbent assay (ELISA) (DuoSet; R&D) according to the manufacturer's instructions; the experiment was performed in triplicate.
| RESULTS |
|---|
|
|
|---|
Expression of transmembrane receptor RET was found in all retinal layers (Fig. 1A and B). Similar expression patterns were found for GFR
-1 (C and D), GFR
-2 (E and F), and GFR
-3 (G and H), thus indicating the possibility of receptor expression on membranes of RMG, since cell bodies of RMG are located in the INL and extensive RMG processes penetrate through all retinal layers. Costaining with the cellular RMG marker GS (Fig. 1A, C, E and G) supported this hypothesis. In order to localize precisely the site of expression, sections were additionally costained with antibodies against GLAST, a membrane glutamate receptor expressed in RMG (39, 43). Costaining with GLAST produced exact colocalization in overlay images, indicating that receptor components for GDNF, NRTN, and ARTN are indeed confined to the RMG membrane (Fig. 1B, D, F, and H). The fluorescence signal observed for PR inner and outer segments is due to autofluorescence and was revealed by comparison with negative controls taken at similar exposure times as pictures of RET and GLAST immunolabelings (omission of primary antibodies, Fig. 1I and K).
|
RT-PCR analysis of mRNA prepared from porcine retina, freshly isolated RMG, and RMG cultured in vitro for 2 weeks showed that whole retina and freshly isolated RMG express RET, GFR
-1, GFR
-2, and GFR
-3 and that RMG cells retained expression of these components after 2 weeks in culture (Fig. 2A, B, and C). Although GDNF itself was not expressed in freshly isolated RMG, its expression increased after 2 weeks in vitro, indicating the establishment of an autocrine activation loop. No expression of GDNF receptor components was found in freshly isolated PR (Fig. 2D); although those preparations yield highly enriched PR (48), they are contaminated, e.g., by RMG, as can be seen by signals for the RMG markers vimentin, GS, and GLAST. Preparations of RMG yield those cells at a purity of approximately 75% on day 1 (23), and those preparations do show expression of receptor components. Additionally, there is expression of rhodopsin in these preparations, reflecting the residual proportion of photoreceptors. Most interestingly, mRNA for rhodopsin is still detectable in RMG at day 14, when those cells are grown in vitro to a purity of above 97% (23). This underlines the difficulties in preparation of cell-specific mRNA pools from complex mixtures.
|
|
-1, GFR
-2, and GFR
-3 in RMG, we found that all three ligands (GDNF, NRTN, and ARTN) could activate signaling cascades in RMG in vitro. Five minutes of GDNF stimulation led to maximum phosphorylation of both MEK and ERK (Fig. 4A). Similar signaling cascades were also activated following stimulation with NRTN and ARTN (Fig. 4B and C). ERK phosphorylation was completely blocked by application of the MEK inhibitor U0126. Whereas GDNF led to strong phosphorylation of SAPK after 5 min, stimulation with ARTN resulted in weaker phosphorylation; NRTN induced SAPK phosphorylation after 10 min. In all three cases, SAPK activation could be partially blocked by the phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor LY294002, indicating that SAPK phosphorylation may be partly induced by active PI 3-kinase. SAPK phosphorylation was completely blocked by the MEK inhibitor U0126. PKB/AKT was phosphorylated by stimulation with NRTN, ARTN, and GDNF at 1, 5, and 10 min, respectively. This phosphorylation was completely blocked by addition of the PI 3-kinase inhibitor LY294002. PKB/AKT phosphorylation was also blocked by the MEK inhibitor U0126.
|
|
GDNF activates ERK in cells of the inner nuclear layer in retinal explants. In order to confirm that GDNF is able to induce signaling in intact retina, we dissected fresh porcine retina and immediately treated it with GDNF or medium alone for 20 min. Tissue samples were then fixed, cryopreserved, and sectioned. Immunohistochemical staining for pERK showed intensely positive areas close to nuclei of cells in the INL and additionally in the inner plexiform layer (IPL) and ganglion cell layer (GCL) of GDNF-treated sections compared to untreated sections (Fig. 6A). Coimmunolabeling for glia-specific marker GS reveals a colocalization of all pERK-positive signals with glial cells (Fig. 6B). Quantification of pERK-positive signals within the INL revealed a significant (P < 0.001) increase in response to GDNF stimulation (Fig. 6C).
|
|
FGF-2 prolongs survival of porcine photoreceptors in vitro. Although the results of our studies indicate that GDNF targets RMG rather than PR in porcine retina, we wanted to investigate direct protective effects of GFLs on PR. GDNF, NRTN, and ARTN were applied to porcine PR in vitro, and survival was monitored by a calcein-esterase assay. In accordance with our hypothesis, neither of the tested GFLs (at concentrations of 100 ng/ml and 500 ng/ml) prolonged survival of PR compared to medium alone (Fig. 8A).
|
| DISCUSSION |
|---|
|
|
|---|
Retinal Mueller glial cells as target cells for GDNF-induced signaling in porcine retina. One of the most effective molecules in rescuing PR function thus far has been GDNF, which rescued PR at both morphological and functional levels in the rd1 mouse model of retinal degeneration (19). The molecular mechanisms of GDNF-induced PR rescue have not been resolved to date but are a fundamental prerequisite for therapeutic application of this molecule. In our study, we examined the expression of GDNF receptor components in the retina. The porcine retina was selected as a model due to its high density of cone cells (24), as well as the close similarity between porcine and human eyes with respect to dimension and anatomical and physiological features (36, 49).
We found that the transmembrane receptor RET, as well as GDNF coreceptor GFR
-1, was not expressed by PR but rather by RMG in porcine retina. In addition to GFR
-1, RMG express the coreceptors necessary for NRTN and ARTN signaling: GFR
-2 and GFR
-3. Studies on the expression of GDNF receptor components in rat retina localized RET and GFR
-1 in PR, the inner nuclear layer, inner plexiform layer, and ganglion cell layer (27), suggesting, among other cells, a localization on RMG, whereas Harada and coworkers (20) have reported expression of GFR
-1 and GFR
-2 receptors mainly in PR. Other evidence has reported GFR
-1 expression in retinal ganglion cells, RMG, and PR (30). These discrepancies have been proposed to reflect specific differences between the rat strains used for the studies (20). Additionally, there are indications that retinae of rodents and other mammals differ in the expression and distribution of neurotrophic factor receptors. As shown for CNTFR
, its expression is absent in PR of adult and developing rodent retinas but rather consistently found in rods and cones of nonrodent mammals, including pigs (6). With regard to GDNF, our findings that GFR
receptors and RET are absent from PR but abundant on RMG lead to the conclusion that, in porcine retina, the neurotrophic effect exerted by GDNF is transduced not directly to PR but indirectly via RMG.
GDNF has been found to signal via NCAM/GFR
-1 complexes in the absence of Ret. Thus, the absence of Ret receptors on PR may still leave the possibility of Ret-independent signaling. Therefore, we investigated here whether GDNF could prolong survival of photoreceptors directly. We found that neither GDNF nor NRTN or ARTN could prolong survival of PR in vitro, even when applied at similarly high concentrations to FGF-2, which in contrast to the tested GFLs was found to prolong survival of PR (Fig. 8). This underlines that even though there is expression of NCAM on PR (Fig. 5A) (5, 16), this receptor does not trigger GFL-induced PR survival in vitro.
There has been increasing evidence for the crucial role of RMG in prolonging PR survival during progressive retinal degenerations (57), and intravitreous injection of brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), or FGF-2 in eyes of wild-type or mutant rats and mice resulted in increased pERK and c-fos immunostaining in cells of the inner retina, particularly RMG but not PR (52, 53). In accordance with activation of RMG by these factors, we propose here that a similar indirect survival-promoting pathway is induced following GDNF application.
GDNF-, NRTN-, and ARTN-induced signaling in RMG. In order to examine molecular action of GDNF in detail, we used pure primary cell cultures of porcine RMG (23) as a tool to address GDNF-induced signaling exclusively in a GDNF-targeted retinal cell. We found that GDNF, as well as NRTN and ARTN, induced several distinct signaling cascades in primary RMG: MEK/ERK, SAPK, and PKB/AKT, which have been previously described to be activated by those ligands (recently reviewed in reference 26). However, the majority of studies were performed on cell lines, especially those expressing constitutively active RET mutations derived from multiple endocrine neoplasia (MEN2A and MEN2B). Most interestingly, our study revealed considerable cross talk between the activated signaling cascades. Our results with MEK inhibitor U0126 (13) demonstrated that GDNF-, NRTN-, and ARTN-induced MEK activation not only triggers ERK but also regulates SAPK and PKB/AKT phosphorylation (see Fig. 9). This could result from either cross talk or unspecific inhibition by the compound U0126. U0126 has been reported to inhibit other kinases than MEK (10) to some extent (mostly to residual 80% activity), but unspecific inhibition of PI3K has not been examined. Furthermore, as we do not know the upstream kinase involved in phosphorylation of SAPK observed here, we can in both cases not exclude unspecific inhibition by U0126. However, the observed complete inhibition of PKB/AKT and SAPK phosphorylation most likely derives not exclusively from unspecific inhibition alone but additionally from cross talk between activated signaling cascades, because unspecific action alone is not expected to block phosphorylation completely. There has been one report about EGF stimulation of 3T3 cells where inhibition of mitogen-activated protein kinase (MAPK) cascade with U0126 stimulated PI 3-kinase-dependent phosphorylation of glycogen synthase kinase 3 (GSK3) (46), which implies cross talk between the MAPK and PKB/AKT cascades. Communications between the MEK/ERK and SAPK pathways have also been proposed in growth factor-stimulated epithelial layers of the porcine lens. There, MEK inhibition with U0126 led to decreased SAPK phosphorylation, suggesting close association of MEK/ERK with the SAPK cascade (58). Furthermore, in our study, the PI 3-kinase inhibitor LY294002 (50) blocked PKB/AKT phosphorylation completely and reduced SAPK phosphorylation. SAPK may thus be activated by at least two kinases in primary RMG: MEK and PI 3-kinase, whereby a complete block of SAPK phosphorylation occurs only through MEK inhibition; PI 3-kinase inhibition is only able to reduce SAPK phosphorylation. Although reduced SAPK phosphorylation may result from unspecific action of LY294002 (no data exist about possible unspecific inhibition of LY294002 on the classical SAPK-activating kinase MKK4), it may also indicate that MEK acts on an unidentified target kinase, which itself activates PI 3-kinase. GDNF, NRTN, and ARTN all activated similar signaling cascades in this study, which is consistent with previous reports (2, 26), but the time course of activation for phosphorylation of PKB/AKT was remarkably different: stimulation with NRTN, ARTN, and GDNF resulted in phosphorylation of PKB/AKT after 1, 5, and 10 min, respectively. The very rapid phosphorylation of PKP/AKT following NRTN stimulation may indicate recruitment of different adapter proteins to the activated RET receptor, in contrast to the considerably later activation of PKB/AKT through GDNF stimulation. Moreover, we consistently observed GFL-associated different SAPK/JNK phosphorylation intensities: whereas GDNF induced strong phosphorylation, NRTN and ARTN resulted in reduced or very weak phosphorylation of SAPK/JNK, respectively. This indicates differential triggering of signal intensities by different GFLs. Together, these findings underline that although these GFLs signal through the same transmembrane receptor RET (3) and induce phosphorylation at similar tyrosine residues of RET, the intracellular signaling dynamics are indeed distinct.
|
Given that GDNF has been shown to rescue PR in the rd1 mouse and our own results indicate that RMG are the target cells of GDNF in the porcine retina, we specifically screened for GDNF-induced expression changes in secreted neuroprotective molecules. We found that RMG indeed respond to GDNF application with an upregulation of FGF-2 expression. This is in agreement with the observations of Harada and coworkers (20), who reported GDNF-induced upregulation of FGF-2 in rat RMG in vitro. Furthermore, subretinal injection of NT-3 prior to light-induced retinal degeneration in mice (21) resulted in upregulation of FGF-2 expression in RMG. This may therefore represent a general pathway for retinal neuroprotection (53, 57). Moreover, we found increased FGF-2 secretion stimulated by GDNF, NRTN, and ARTN, which may support paracrine action of those factors. The increased FGF-2 secretion is entirely dependent on GFL-induced MEK activation, since the presence of U0126 completely abolished enhanced secretion. Since the amount of secreted FGF-2 decreased below control levels in the presence of U0126, this indicates that the presence of RMG-derived GDNF alone triggers basic levels of FGF-2 secretion.
We functionally verified that neither GDNF, NRTN, nor ARTN has a direct survival-supporting effect on PR (Fig. 8), whereas application of FGF-2 prolonged survival of PR in vitro. The ability of FGF-2 to enhance survival of postnatal rat PR has been demonstrated (17), and indications for the long-term survival-promoting effect of FGF-2 (after 2 weeks in vitro) on porcine PR following repeated application (48) also exist. However, the observed GDNF-induced secretion of FGF-2 occurred within 16 h, and we therefore addressed the question of whether in vitro FGF-2 application would show a faster survival-promoting effect in our system. Indeed, we found a pronounced and concentration-dependent effect of FGF-2 on survival of PR in vitro, detectable already 2 days after application and most pronounced after 5 days in vitro. Based on these results, we propose the following model for GDNF-induced neuroprotection of porcine PR. GDNF activates distinct intracellular signaling pathways in RMG, namely, MEK/ERK, AKT/PKB, and SAPK/JNK. Activated MEK results in enhanced FGF-2 transcription, and FGF-2 is released from RMG and subsequently acts as a survival factor for neighboring PR (Fig. 9).
However, for testing the functionality of the suggested paracrine pathway, treatment of retinal explants with GDNF in the absence versus the presence of, e.g., MEK inhibitor U0126 would be necessary to quench the GDNF-induced production of FGF-2. As U0126 targets MEK not only in RMG but in all cells including photoreceptors when applied to whole retina, U0126 application leads to diminished photoreceptor survival as assessed in vitro (data not shown) and in vivo, since FGF-2-induced survival signaling involves MEK in photoreceptors (28). Furthermore, it has been reported that U0126 induces glutamate release from neurons in an ERK-independent manner (41), thus complicating the expected effects of U0126 when applied to whole retina. Another observation in retinal explants is that the explanting procedure alone leads to increased FGF-2 production in the explanted retina (P. Ekstrom, Lund University, personal communication of unpublished results), an event that may be interpreted as an intrinsic survival attempt. Taken together, pharmacological interference experiments performed on intact retina are not expected to further elucidate the GDNF-induced survival mechanism.
Is FGF-2 the survival-promoting molecule in vivo?
The functional importance of this model of PR support through RMG is strengthened by the finding that RMG express three different coreceptor types for GDNF family ligand signaling, thus providing a redundancy also seen with striatal and hippocampal neurons (31). Nevertheless, although FGF-2 is unambiguously upregulated in response to GDNF and does in contrast to GDNF prolong survival of PR in vitro, the question remains open of whether this is the molecule responsible for the GDNF-induced functional rescue of PR in the rd1 mouse (19). We observed here that 1 x 105 RMG secrete approximately 50 pg/ml FGF-2 in 12 h under in vitro conditions (measured by ELISA), whereas the effective amount of exogenous FGF-2 necessary to prolong PR survival was 500 ng/ml. However, this discrepancy could be explained by taking into account that secreted FGF-2 in vitro is diluted into the culture medium (100 µl medium volume per well and 1 x 105 RMG, or 1 nl per cell) by more than a factor of 1,000 when compared to the in vivo situation. In vivo, the extracellular space (interphotoreceptor matrix; IPM) bordering RMG and absorbing the secreted material can be estimated at 0.7 pl per RMG cell. This rather small volume can be calculated based on an estimated number of 1.5 x 107 RMG per porcine retina (24, 44) and on an estimation of total IPM volume for porcine eyes of
10 µl. IPM volume for bovine eyes has been calculated at 30 µl (30 to 100 µl) (1) and may thus be expected to be smaller for smaller porcine eyes. Thus, in vivo, RMG-secreted FGF-2 may be concentrated by more than 3 logs compared to the amounts measured by ELISA in vitro. Further, FGF-2 may be accumulated in vivo for longer time periods. If under GDNF stimulation, 50 pg/ml is secreted during 16 h in the in vitro experiment (after 48 h, we observed 230 ± 17.2 pg/ml FGF-2; data not shown), the cumulative secretion after 5 days would be approximately 500 pg/ml. Together, these assumptions may account for large amounts of FGF-2 in vivo, although no definitive proof is available. Additionally, FGF-2 released in vivo into the extracellular matrix (ECM) is likely sequestered by low-affinity FGF receptors (heparan sulfate proteoglycans), thus increasing local concentrations (8, 45), protecting the factor from inactivation (51), and presenting it to high-affinity FGF-receptors (56). However, even if sufficiently high levels of FGF-2 are reached in vivo, direct injections of FGF-2 in animal models of retinal degeneration have so far only been shown to increase PR numbers (33, 47), but failed to improve electroretinogram recordings (32, 54), indicating it is insufficient for functional rescue. Thus, we hypothesize that GDNF modulates the expression of additional molecules in RMG, which in turn enables the preservation of PR function. Identification of these GDNF-induced molecules is a part of our ongoing and future studies, where the porcine retina represents an excellent model, as it is cone rich and it is a tissue in which RMG have been recently demonstrated to secrete a factor specifically promoting cone survival in vitro (4). Although specific information on this factor is presently unavailable, it remains an intriguing candidate for being targeted by GDNF-induced signaling in RMG.
GDNF has been repeatedly suggested in the context of future therapeutic regimens, presented either alone or combined with a cell-based therapy/delivery. Previous studies in gene and cell therapy have revealed that application of such neurotrophic cytokines prior to an in-depth understanding of their mechanism of action bears unpredictable risks for the patients treated (12). Thus, this study contributes to a better understanding of GDNF's mechanism of action on primary retinal cells and tissue and may contribute to a more rationalized risk assessment on this promising factor for future clinical trials.
| ACKNOWLEDGMENTS |
|---|
This work was funded by EU grants PRORET QLK6-CT-200000569, PRO-AGE-RET QLK6-CT-2001-00385, RETNET MRTN-CT-2003-504003, EVI-GENORET LSHG-CT-2005 512036, and INTERACTION PROTEOME LSHG-CT-2003-505520 and by funding from the German Federal Ministry of Education and Research (BMBF-Proteomics 031U108A/031U208A).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Airaksinen, M. S., and M. Saarma. 2002. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci 3:383-394.[CrossRef][Medline]
3. Airaksinen, M. S., A. Titievsky, and M. Saarma. 1999. GDNF family neurotrophic factor signaling: four masters, one servant? Mol. Cell. Neurosci. 13:313-325.[CrossRef][Medline]
4. Balse, E., L.-H. Tessier, C. Fuchs, V. Forster, J. A. Sahel, and S. Picaud. 2005. Purification of mammalian cone photoreceptors by lectin panning and the enhancement of their survival in glia-conditioned medium. Investig. Ophthalmol. Vis. Sci. 46:367-374.
5. Bartsch, U., F. Kirchhoff, and M. Schachner. 1990. Highly sialylated N-CAM is expressed in adult mouse optic nerve and retina. J. Neurocytol. 19:550-565.[CrossRef][Medline]
6. Beltran, W. A., H. Rohrer, and G. D. Aguirre. 2005. Immunolocalization of ciliary neurotrophic factor receptor alpha (CNTFRalpha) in mammalian photoreceptor cells. Mol. Vis. 11:232-244.[Medline]
7. Bringmann, A., and A. Reichenbach. 2001. Role of Muller cells in retinal degenerations. Front. Biosci. 6:E72-E92.[Medline]
8. Carey, D. J. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327:1-16.
9. Chaum, E. 2003. Retinal neuroprotection by growth factors: a mechanistic perspective. J. Cell. Biochem. 88:57-75.[CrossRef][Medline]
10. Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95-105.[CrossRef][Medline]
11. Derouiche, A., and T. Rauen. 1995. Coincidence of L-glutamate/L-aspartate transporter (GLAST) and glutamine synthetase (GS) immunoreactions in retinal glia: evidence for coupling of GLAST and GS in transmitter clearance. J. Neurosci. Res. 42:131-143.[CrossRef][Medline]
12. Dittrich, F., H. Thoenen, and M. Sendtner. 1994. Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat. Ann. Neurol. 35:151-163.[CrossRef][Medline]
13. Duncia, J. V., J. B. Santella III, C. A. Higley, W. J. Pitts, J. Wityak, W. E. Frietze, F. W. Rankin, J. H. Sun, R. A. Earl, A. C. Tabaka, C. A. Teleha, K. F. Blom, M. F. Favata, E. J. Manos, A. J. Daulerio, D. A. Stradley, K. Horiuchi, R. A. Copeland, P. A. Scherle, J. M. Trzaskos, R. L. Magolda, G. L. Trainor, R. R. Wexler, F. W. Hobbs, and R. E. Olson. 1998. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8:2839-2844.[CrossRef][Medline]
14. Encinas, M., M. G. Tansey, B. A. Tsui-Pierchala, J. X. Comella, J. Milbrandt, and E. M. Johnson, Jr. 2001. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J. Neurosci. 21:1464-1472.
15. Faktorovich, E. G., R. H. Steinberg, D. Yasumura, M. T. Matthes, and M. M. LaVail. 1990. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 347:83-86.[CrossRef][Medline]
16. Fliesler, S. J., G. J. Cole, and A. J. Adler. 1990. Neural cell adhesion molecule (NCAM) in adult vertebrate retinas: tissue localization and evidence against its role in retina-pigment epithelium adhesion. Exp. Eye Res. 50:475-482.[CrossRef][Medline]
17. Fontaine, V., N. Kinkl, J. Sahel, H. Dreyfus, and D. Hicks. 1998. Survival of purified rat photoreceptors in vitro is stimulated directly by fibroblast growth factor-2. J. Neurosci. 18:9662-9672.
18. Forster, V., H. Dreyfus, and D. Hicks. 1999. Adult mammalian retina, p. 579-585. In L. W. Haynes (ed.), The neuron in tissue culture, vol. 18. John Wiley & Sons, Chichester, United Kingdom.
19. Frasson, M., S. Picaud, T. Leveillard, M. Simonutti, S. Mohand-Said, H. Dreyfus, D. Hicks, and J. Sahel. 1999. Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse. Investig. Ophthalmol. Vis. Sci. 40:2724-2734.
20. Harada, C., T. Harada, H.-M. A. Quah, F. Maekawa, K. Yoshida, S. Ohno, K. Wada, L. F. Parada, and K. Tanaka. 2003. Potential role of glial cell line-derived neurotrophic factor receptors in Muller glial cells during light-induced retinal degeneration. Neuroscience 122:229-235.[CrossRef][Medline]
21. Harada, T., C. Harada, N. Nakayama, S. Okuyama, K. Yoshida, S. Kohsaka, H. Matsuda, and K. Wada. 2000. Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration. Neuron 26:533-541.[CrossRef][Medline]
22. Harper, J. F. 1984. Peritz' F test: basic program of a robust multiple comparison test for statistical analysis of all differences among group means. Comput. Biol. Med. 14:437-445.[CrossRef][Medline]
23. Hauck, S. M., S. Suppmann, and M. Ueffing. 2003. Proteomic profiling of primary retinal Muller glia cells reveals a shift in expression patterns upon adaptation to in vitro conditions. Glia 44:251-263.[CrossRef][Medline]
24. Hendrickson, A., and D. Hicks. 2002. Distribution and density of medium- and short-wavelength selective cones in the domestic pig retina. Exp. Eye Res. 74:435-444.[CrossRef][Medline]
25. Hims, M. M., S. P. Diager, and C. F. Inglehearn. 2003. Retinitis pigmentosa: genes, proteins and prospects. Dev. Ophthalmol. 37:109-125.[CrossRef][Medline]
26. Ichihara, M., Y. Murakumo, and M. Takahashi. 2004. RET and neuroendocrine tumors. Cancer Lett. 204:197-211.[CrossRef][Medline]
27. Jomary, C., R. M. Darrow, P. Wong, D. T. Organisciak, and S. E. Jones. 2004. Expression of neurturin, glial cell line-derived neurotrophic factor, and their receptor components in light-induced retinal degeneration. Investig. Ophthalmol. Vis. Sci. 45:1240-1246.
28. Kinkl, N., J. Sahel, and D. Hicks. 2001. Alternate FGF2-ERK1/2 signaling pathways in retinal photoreceptor and glial cells in vitro. J. Biol. Chem. 276:43871-43878.
29. Koeberle, P. D., and A. K. Ball. 1998. Effects of GDNF on retinal ganglion cell survival following axotomy. Vision Res. 38:1505-1515.[CrossRef][Medline]
30. Koeberle, P. D., and A. K. Ball. 2002. Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined effects with glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor. Neuroscience 110:555-567.[CrossRef][Medline]
31. Kokaia, Z., M. S. Airaksinen, A. Nanobashvili, E. Larsson, E. Kujamaki, O. Lindvall, and M. Saarma. 1999. GDNF family ligands and receptors are differentially regulated after brain insults in the rat. Eur. J. Neurosci. 11:1202-1216.[CrossRef][Medline]
32. Lau, D., L. H. McGee, S. Zhou, K. G. Rendahl, W. C. Manning, J. A. Escobedo, and J. G. Flannery. 2000. Retinal degeneration is slowed in transgenic rats by AAV-mediated delivery of FGF-2. Investig. Ophthalmol. Vis. Sci. 41:3622-3633.
33. LaVail, M. M., D. Yasumura, M. T. Matthes, C. Lau-Villacorta, K. Unoki, C.-H. Sung, and R. H. Steinberg. 1998. Protection of mouse photoreceptors by survival factors in retinal degenerations. Investig. Ophthalmol. Vis. Sci. 39:592-602.
34. Lewis, G. P., P. A. Erickson, D. D. Kaska, and S. K. Fisher. 1988. An immunocytochemical comparison of Muller cells and astrocytes in the cat retina. Exp. Eye Res. 47:839-853.[CrossRef][Medline]
35. Lin, L. F., D. H. Doherty, J. D. Lile, S. Bektesh, and F. Collins. 1993. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
36. McMenamin, P. G., and R. J. Steptoe. 1991. Normal anatomy of the aqueous humour outflow system in the domestic pig eye. J. Anat. 178:65-77.[Medline]
37. Morgan, J. M., H. Navabi, and B. Jasani. 1997. Role of calcium chelation in high-temperature antigen retrieval at different pH values. J. Pathol. 182:233-237.[CrossRef][Medline]
38. Nosrat, C. A., A. Tomac, E. Lindqvist, S. Lindskog, C. Humpel, I. Stromberg, T. Ebendal, B. J. Hoffer, and L. Olson. 1996. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res. 286:191-207.[CrossRef][Medline]
39. Otori, Y., S. Shimada, K. Tanaka, I. Ishimoto, Y. Tano, and M. Tohyama. 1994. Marked increase in glutamate-aspartate transporter (GLAST/GluT-1) mRNA following transient retinal ischemia. Brain Res. Mol. Brain Res. 27:310-314.[Medline]
40. Paratcha, G., F. Ledda, and C. F. Ibanez. 2003. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113:867-879.[CrossRef][Medline]
41. Pereira, D. B., A. P. Carvalho, and C. B. Duarte. 2002. Non-specific effects of the MEK inhibitors PD098,059 and U0126 on glutamate release from hippocampal synaptosomes. Neuropharmacology 42:9-19.[CrossRef][Medline]
42. Priglinger, S. G., C. A. May, A. S. Neubauer, C. S. Alge, C. L. Schonfeld, A. Kampik, and U. Welge-Lussen. 2003. Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes. Investig. Ophthalmol. Vis. Sci. 44:355-364.
43. Rauen, T., J. D. Rothstein, and H. Wassle. 1996. Differential expression of three glutamate transporter subtypes in the rat retina. Cell Tissue Res. 286:325-336.[CrossRef][Medline]
44. Reichenbach, A. 1999. Neuroglia-das andere zelluläre Element im Nervensystem: die Müllersche Gliazelle. Pharmacia & Upjohn GmbH, Erlangen, Germany.
45. Schonherr, E., and H. J. Hausser. 2000. Extracellular matrix and cytokines: a functional unit. Dev. Immunol. 7:89-101.[Medline]
46. Shaw, M., and P. Cohen. 1999. Role of protein kinase B and the MAP kinase cascade in mediating the EGF-dependent inhibition of glycogen synthase kinase 3 in Swiss 3T3 cells. FEBS Lett. 461:120-124.[CrossRef][Medline]
47. Spencer, B., S. Agarwala, L. Gentry, and C. R. Brandt. 2001. HSV-1 vector-delivered FGF2 to the retina is neuroprotective but does not preserve functional responses. Mol. Ther. 3:746-756.[CrossRef][Medline]
48. Traverso, V., N. Kinkl, L. Grimm, J. Sahel, and D. Hicks. 2003. Basic fibroblast and epidermal growth factors stimulate survival in adult porcine photoreceptor cell cultures. Investig. Ophthalmol. Vis. Sci. 44:4550-4558.
49. Vestre, W. A. 1984. Porcine ophthalmology. Vet. Clin. N. Am. Large Anim. Pract. 6:667-676.
50. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241-5248.
51. Vlodavsky, I., H. Q. Miao, B. Medalion, P. Danagher, and D. Ron. 1996. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 15:177-186.[CrossRef][Medline]
52. Wahlin, K. J., R. Adler, D. J. Zack, and P. A. Campochiaro. 2001. Neurotrophic signaling in normal and degenerating rodent retinas. Exp. Eye Res. 73:693-701.[CrossRef][Medline]
53. Wahlin, K. J., P. A. Campochiaro, D. J. Zack, and R. Adler. 2000. Neurotrophic factors cause activation of intracellular signaling pathways in Muller cells and other cells of the inner retina, but not photoreceptors. Investig. Ophthalmol. Vis. Sci. 41:927-936.
54. Yamada, H., E. Yamada, A. Ando, N. Esumi, N. Bora, J. Saikia, C. H. Sung, D. J. Zack, and P. A. Campochiaro. 2001. Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. Am. J. Pathol. 159:1113-1120.
55. Yan, Q., J. Wang, C. R. Matheson, and J. L. Urich. 1999. Glial cell line-derived neurotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). J. Neurobiol. 38:382-390.[CrossRef][Medline]
56. Yayon, A., M. Klagsbrun, J. D. Esko, P. Leder, and D. M. Ornitz. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-848.[CrossRef][Medline]
57. Zack, D. J. 2000. Neurotrophic rescue of photoreceptors: are Muller cells the mediators of survival? Neuron 26:285-286.[CrossRef][Medline]
58. Zatechka, S. D., Jr., and M. F. Lou. 2002. Studies of the mitogen-activated protein kinases and phosphatidylinositol-3 kinase in the lens. 1. The mitogenic and stress responses. Exp. Eye Res. 74:703-717.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||